EA007297B1 - Производные n-бифенилметиламиноциклоалканкарбоксамида с заместителем на метиле в качестве антагонистов брадикинина - Google Patents

Производные n-бифенилметиламиноциклоалканкарбоксамида с заместителем на метиле в качестве антагонистов брадикинина Download PDF

Info

Publication number
EA007297B1
EA007297B1 EA200401054A EA200401054A EA007297B1 EA 007297 B1 EA007297 B1 EA 007297B1 EA 200401054 A EA200401054 A EA 200401054A EA 200401054 A EA200401054 A EA 200401054A EA 007297 B1 EA007297 B1 EA 007297B1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
silt
oxadiazol
amino
pyrimidine
Prior art date
Application number
EA200401054A
Other languages
English (en)
Russian (ru)
Other versions
EA200401054A1 (ru
Inventor
Майкл Р. Вуд
Невилл Дж. Энтони
Марк Дж. Бок
Донг-Мей Фенг
Скотт Д. Кудук
Дай-Си Су
Дженни Миу-чун Вэй
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of EA200401054A1 publication Critical patent/EA200401054A1/ru
Publication of EA007297B1 publication Critical patent/EA007297B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA200401054A 2002-02-08 2003-02-04 Производные n-бифенилметиламиноциклоалканкарбоксамида с заместителем на метиле в качестве антагонистов брадикинина EA007297B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35506202P 2002-02-08 2002-02-08
US41017202P 2002-09-12 2002-09-12
PCT/US2003/003338 WO2003066577A1 (en) 2002-02-08 2003-02-04 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists

Publications (2)

Publication Number Publication Date
EA200401054A1 EA200401054A1 (ru) 2005-02-24
EA007297B1 true EA007297B1 (ru) 2006-08-25

Family

ID=27737481

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401054A EA007297B1 (ru) 2002-02-08 2003-02-04 Производные n-бифенилметиламиноциклоалканкарбоксамида с заместителем на метиле в качестве антагонистов брадикинина

Country Status (27)

Country Link
US (2) US6919343B2 (US07981874-20110719-C00313.png)
EP (1) EP1501787B1 (US07981874-20110719-C00313.png)
JP (1) JP4098249B2 (US07981874-20110719-C00313.png)
KR (1) KR20040083440A (US07981874-20110719-C00313.png)
CN (1) CN1328247C (US07981874-20110719-C00313.png)
AR (1) AR038377A1 (US07981874-20110719-C00313.png)
AT (1) ATE309202T1 (US07981874-20110719-C00313.png)
AU (1) AU2003216169B2 (US07981874-20110719-C00313.png)
BR (1) BR0307508A (US07981874-20110719-C00313.png)
CA (1) CA2474373C (US07981874-20110719-C00313.png)
DE (1) DE60302240T2 (US07981874-20110719-C00313.png)
DK (1) DK1501787T3 (US07981874-20110719-C00313.png)
EA (1) EA007297B1 (US07981874-20110719-C00313.png)
EC (1) ECSP045217A (US07981874-20110719-C00313.png)
ES (1) ES2250899T3 (US07981874-20110719-C00313.png)
HR (1) HRP20040677A2 (US07981874-20110719-C00313.png)
IS (1) IS7372A (US07981874-20110719-C00313.png)
JO (1) JO2356B1 (US07981874-20110719-C00313.png)
MA (1) MA27108A1 (US07981874-20110719-C00313.png)
MX (1) MXPA04007660A (US07981874-20110719-C00313.png)
NO (1) NO20043739L (US07981874-20110719-C00313.png)
NZ (1) NZ534062A (US07981874-20110719-C00313.png)
PE (1) PE20030986A1 (US07981874-20110719-C00313.png)
PL (1) PL371664A1 (US07981874-20110719-C00313.png)
RS (1) RS65404A (US07981874-20110719-C00313.png)
TW (1) TWI259079B (US07981874-20110719-C00313.png)
WO (1) WO2003066577A1 (US07981874-20110719-C00313.png)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057671A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Compose biaryle et son utilisation
AU2003217728B2 (en) * 2002-02-08 2008-11-20 Merck Sharp & Dohme Corp. N-Biphenylmethyl aminocycloalkanecarboxamide derivatives
KR20050033660A (ko) * 2002-08-29 2005-04-12 머크 앤드 캄파니 인코포레이티드 Ｎ-바이아릴메틸 아미노사이클로알칸카복스아미드 유도체
EP1572678A4 (en) * 2002-12-19 2008-05-07 Elan Pharm Inc SUBSTITUTED N-PHENYL SULPHONAMIDES ALSBRADYKININ ANTAGONISTS
EP1654232A4 (en) * 2003-08-07 2008-11-12 Merck & Co Inc N- (BIARYLMETHYL) AMINOCYCLOPROPANECARBOXAMIDES WITH SULFONYL SUBSTITUTION
JP4585522B2 (ja) * 2003-12-22 2010-11-24 メルク・シャープ・エンド・ドーム・コーポレイション ブラジキニン拮抗物質又は逆作用物質としてのアルファ−ヒドロキシアミド
ATE423114T1 (de) * 2004-03-02 2009-03-15 Merck & Co Inc Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten
US20050245543A1 (en) * 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
WO2006020291A2 (en) * 2004-08-02 2006-02-23 Bebaas, Inc. Vitamin b12 compositions
DE102004060542A1 (de) * 2004-12-16 2006-07-06 Sanofi-Aventis Deutschland Gmbh Hydroxybiphenyl-Carbonsäuren und Derivate, Verfahren zu deren Herstellung und deren Verwendung
JP4966202B2 (ja) 2004-12-24 2012-07-04 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 治療または予防のための方法
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
US8551950B2 (en) 2006-03-20 2013-10-08 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis of inflammatory pain
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
MX2009013332A (es) 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
AR070750A1 (es) 2007-08-29 2010-05-05 Boehringer Ingelheim Int Compuestos b1-antagonistas, sus sales farmaceuticamente compatibles, medicamentos que contienen dichos compuestos, uso de los mismos para preparar medicamentos y procedimientoo de preparacion de un medicamento
US20090270394A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Cyclylamine derivatives as calcium channel blockers
WO2010097374A1 (de) * 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Verbindungen als bradykinin-b1-antagonisten
WO2010097373A1 (de) * 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Verbindungen als bradykinin b1 antagonisten
JP5629274B2 (ja) * 2009-02-26 2014-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブラジキニンｂ１アンタゴニストとしての化合物
US10457810B2 (en) 2009-08-24 2019-10-29 Board Of Trustees Of Michigan State University Densified biomass products containing pretreated biomass fibers
JP5603955B2 (ja) * 2010-02-23 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブラジキニンｂ１拮抗薬としての化合物
CN102939388B (zh) 2010-04-19 2016-08-03 密歇根州立大学董事会 可消化木质纤维素生物质和提取物及其制备方法
US8937073B2 (en) * 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
HUP1000598A2 (en) * 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
US8912221B2 (en) * 2010-12-27 2014-12-16 Hoffmann-La Roche Inc. Biaryl amide derivatives
US8592426B2 (en) * 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
JP2021501785A (ja) * 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
TWI832295B (zh) 2018-10-11 2024-02-11 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IL99372A0 (en) 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
US5208236A (en) 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
ATE193706T1 (de) 1993-11-16 2000-06-15 Novartis Ag Zyklische aminosäure-derivate mit ace und nep inhibierender aktivität
AU7211696A (en) 1995-09-27 1997-04-17 Ciba-Geigy Ag Treatment of chronic progressive renal failure
FR2743562B1 (fr) 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
US6433185B1 (en) 1996-01-11 2002-08-13 Sanofi-Synthelabo N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them
JP4350306B2 (ja) 1998-04-23 2009-10-21 ノバルティス アクチエンゲゼルシャフト エンドセリン変換酵素のチオール型阻害剤
IL138688A0 (en) 1998-04-23 2001-10-31 Novartis Ag Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
DE10036121A1 (de) 2000-07-25 2002-02-07 Merck Patent Gmbh N-Substituierte-1-amino-1,1-dialkyl-carbonsäurederivate
AU2003217728B2 (en) 2002-02-08 2008-11-20 Merck Sharp & Dohme Corp. N-Biphenylmethyl aminocycloalkanecarboxamide derivatives

Also Published As

Publication number Publication date
ES2250899T3 (es) 2006-04-16
WO2003066577A1 (en) 2003-08-14
MXPA04007660A (es) 2004-11-10
AU2003216169B2 (en) 2008-12-04
CN1328247C (zh) 2007-07-25
IS7372A (is) 2004-07-26
PL371664A1 (en) 2005-06-27
KR20040083440A (ko) 2004-10-01
JO2356B1 (en) 2006-12-12
JP4098249B2 (ja) 2008-06-11
AU2003216169A1 (en) 2003-09-02
ATE309202T1 (de) 2005-11-15
CN1630633A (zh) 2005-06-22
DK1501787T3 (da) 2006-03-20
NO20043739L (no) 2004-10-29
US20050084463A1 (en) 2005-04-21
DE60302240D1 (de) 2005-12-15
ECSP045217A (es) 2004-09-28
EP1501787B1 (en) 2005-11-09
JP2005517006A (ja) 2005-06-09
CA2474373A1 (en) 2003-08-14
MA27108A1 (fr) 2004-12-20
PE20030986A1 (es) 2003-11-19
NZ534062A (en) 2006-06-30
HRP20040677A2 (en) 2005-06-30
EA200401054A1 (ru) 2005-02-24
RS65404A (en) 2007-02-05
DE60302240T2 (de) 2006-07-13
US6919343B2 (en) 2005-07-19
AR038377A1 (es) 2005-01-12
TWI259079B (en) 2006-08-01
US20030220375A1 (en) 2003-11-27
TW200302718A (en) 2003-08-16
BR0307508A (pt) 2004-12-07
EP1501787A1 (en) 2005-02-02
CA2474373C (en) 2009-05-26

Similar Documents

Publication Publication Date Title
EA007297B1 (ru) Производные n-бифенилметиламиноциклоалканкарбоксамида с заместителем на метиле в качестве антагонистов брадикинина
AU2003265674B2 (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
ES2256727T3 (es) Derivados de n-bifenilmetil aminocicloalcanocarboxamida.
EP1706372B1 (en) Alpha-hydroxy amides as bradykinin antagonists or inverse agonists
US7332499B2 (en) Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides
US20040044041A1 (en) 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives
US20040029920A1 (en) 2-(biarylalkyl)amino-3-(heterocyclylcarbonylamino)-pyridine derivatives
ZA200405697B (en) N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substituent on the methyl useful as bradykininantagonists

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU